产品
编 号：F421349
分子式：C21H13F3N2O4
分子量：414.33
分子式：C21H13F3N2O4
分子量：414.33
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
268
In-stock
5mg
640
In-stock
10mg
960
In-stock
50mg
2800
In-stock
结构图
CAS No: 66898-62-2
产品详情
生物活性：
Talniflumate (BA 7602-06) is the proagent of Niflumic acid (HY-B0493), exerting its activity in the body through conversion to niflumic acid by esterase. Talniflumate is an orally active Ca2+-activated Cl- channel (CaCC) blocker. Talniflumate can be used as an analgesic and anti-inflammatory agent in cystic fibrosis mouse model of distal intestinal obstructive syndrome.
体内研究：
Talniflumate (oral chow; 0.4 mg/g; 21 days) significantly increases CF mouse survival from 26 to 77%. It does not alter crypt goblet cell numbers or change intestinal expression of mCLCA3 but tends to decrease crypt mucoid impaction.Animal Model:CF mice with distal intestinal obstructive syndrome (DIOS)
Dosage:0.4 mg/g
Administration:Oral chow; 21 days
Result:Increased survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome.
Talniflumate (BA 7602-06) is the proagent of Niflumic acid (HY-B0493), exerting its activity in the body through conversion to niflumic acid by esterase. Talniflumate is an orally active Ca2+-activated Cl- channel (CaCC) blocker. Talniflumate can be used as an analgesic and anti-inflammatory agent in cystic fibrosis mouse model of distal intestinal obstructive syndrome.
体内研究：
Talniflumate (oral chow; 0.4 mg/g; 21 days) significantly increases CF mouse survival from 26 to 77%. It does not alter crypt goblet cell numbers or change intestinal expression of mCLCA3 but tends to decrease crypt mucoid impaction.Animal Model:CF mice with distal intestinal obstructive syndrome (DIOS)
Dosage:0.4 mg/g
Administration:Oral chow; 21 days
Result:Increased survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备